医学
癌症
临床试验
白斑
肿瘤科
内科学
癌症研究
药理学
作者
Yu‐Hao Liao,Wei‐Yi Chou,Chun‐Wei Chang,Mei‐Chun Lin,Cheng‐Ping Wang,Pei‐Jen Lou,Tseng‐Cheng Chen
出处
期刊:Head & neck
[Wiley]
日期:2023-02-21
卷期号:45 (4): 1045-1059
被引量:14
摘要
Abstract Background Oral cancer causes significant morbidity and mortality. Chemoprevention utilizes medication or natural compounds to reverse oral premalignant lesions and to prevent second primary tumors. Methods A comprehensive PubMed database and Cochrane Library search from 1980 to 2021 was performed using the keywords “leukoplakia,” “oral premalignant lesion,” and “chemoprevention.” Results Chemopreventive agents included retinoids, carotenoids, cyclooxygenase inhibitor, herbal extracts, bleomycin, tyrosine kinase inhibitors, metformin, and immune checkpoint inhibitors. Although some agents demonstrated effect in reducing premalignant lesions and preventing second primary tumors, the results among different studies were highly variable. Conclusions The results of different trials, albeit inconsistent, provided substantial information for future studies. In the era of personalized medicine, future studies will focus on identifying specific biomarkers and molecular profile to monitor and to prevent malignant transformation. Larger trials are warranted to validate the effect of chemopreventive agents.
科研通智能强力驱动
Strongly Powered by AbleSci AI